News | July 24, 2024
Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
To accelerate the development of next-generation radioconjugates to treat cancer
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Subscribe To Our Newsletter & Stay Updated
